Finally, should ongoing Aβ immunotherapy clinical trials with e.g. the promising aducanumab antibody that successfully removes patient brain amyloid 165 be beneficial in AD, a combination therapy with Aβ42 production modifiers or C99-selective inhibitors to maintain low amyloid levels, thereby preventing and/or shifting the onset of AD, might be an ideal and more cost-effective strategy for disease-modification than an immunotherapy alone. This evidence concerns the gene APP and Alzheimer disease.